Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 9/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908373 | 0.86 | SMYD3 (0.56) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL506648 | 0.80 | ALDH1A1 (0.50) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL17253106 | 0.79 | PRKAB2 (0.48) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL3237045 | 0.78 | PRKAB2 (0.50) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL178410 | 0.78 | CNR1 (0.52) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL349519 | 0.78 | KDM4E (0.53) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL244445 | 0.77 | SMYD3 (0.67) | SMYD3PARP1 | |
| SCHEMBL26970993 | 0.77 | PARP1 (0.51) | LMNAPARP1 | |
| SCHEMBL30027907 | 0.77 | PARP1 (0.51) | LMNAPARP1 | |
| SCHEMBL31731804 | 0.76 | CRBN (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101035765-B | Sulfonamide derivatives | HOFFMANN LA ROCHE | 2010-10-13 | — | — | CN | disclosed |
| CN-101747324-A | Sulfonamide derivatives | HOFFMANN LA ROCHE | 2010-06-23 | — | — | CN | disclosed |
| CN-101035765-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | CN | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1768960-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | disclosed |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | BACE1, APP, BACE2 | PRKAA2 1870/4885PRKAB2 3124/4885PRKAG1 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.